BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights – BIOA

Lawsuit Overview - The Gross Law Firm is issuing a notice to shareholders of BioAge Labs, Inc (NASDAQ: BIOA) who purchased shares during the specified class period [1] - Shareholders are encouraged to contact the firm regarding possible lead plaintiff appointment, though appointment is not required to partake in any recovery [1] - The class action lawsuit is on behalf of all shareholders who purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024 [3] Allegations - On December 6, 2024, BioAge announced the discontinuation of the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, due to safety concerns over elevated liver transaminase levels in participants [4] - This announcement was surprising as BioAge had highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs at the time of its IPO less than three months earlier [4] - Following the news, BioAge's stock price declined from $20 09 per share on December 6, 2024 to $4 65 per share on December 7, 2024 [4] Next Steps for Shareholders - Shareholders who purchased BIOA shares during the specified timeframe can register to be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [5] - The deadline to seek to be a lead plaintiff is March 10, 2025, and there is no cost or obligation to participate in the case [5] About The Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investor rights [6] - The firm seeks recovery on behalf of investors who incurred losses due to false and/or misleading statements or the omission of material information by a company, leading to artificial inflation of the company's stock [6]